Skip to main content
OliX Pharmaceuticals, Inc. logo

OliX Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · 226950 ISIN · KR7226950004 KO Manufacturing
Open in API
Filings indexed 365 across all filing types
Latest filing 2023-05-12 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 226950

About OliX Pharmaceuticals, Inc.

https://olixpharma.com

OliX Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the development of therapeutics based on RNA interference (RNAi) technology. The company leverages its proprietary asymmetric siRNA (asiRNA) platform to create treatments that selectively silence disease-causing genes. Its research and development efforts are focused on building a robust pipeline of drug candidates targeting a variety of illnesses with high unmet medical needs. The pipeline has a particular emphasis on ophthalmic and dermal disorders, with key programs addressing conditions such as hypertrophic scars, age-related macular degeneration (AMD), and other fibrotic and ocular diseases.

Recent filings

Filing Released Lang Actions
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Olix' (올릭스(주)) covering the period from January 1, 2023, to March 31, 2023. It contains detailed business descriptions, financial data, and management discussions. In the context of Korean regulatory filings (DART), a '분기보고서' is a comprehensive interim financial report. Therefore, it is classified as an Interim / Quarterly Report (IR). Q1 2023
2023-05-12 Korean
[기재정정]분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company Olix (올릭스(주)) for the period ending March 31, 2023. It contains detailed financial statements, management discussion and analysis, and business operations information. Although it is labeled as a 'Correction Report' (정정신고), it is a comprehensive financial filing that includes substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-12 Korean
투자판단관련주요경영사항(휴젤, 비대흉터치료제(OLX101A) 기술이전 계약 해지)
M&A Activity Classification · 100% confidence The document is a regulatory disclosure from a Korean company (OliX) regarding the termination of a technology transfer agreement with Hugel. It details the nature of the contract, the reason for termination, and the impact on the company's business operations. This type of disclosure is a standard regulatory filing for material corporate events in the Korean market, which does not fit into specific categories like M&A (as it is a termination of a licensing agreement) or legal proceedings, making 'RNS' (Regulatory Filings) the most appropriate classification.
2023-05-10 Korean
투자판단관련주요경영사항(흉터 재건술 이후 재발 억제 보조요법으로서 OLX10010의 유효성 평가를 위한 무작위배정, 이중 맹검, 개체 내 비교, 위약대조, 개념 검증, 2a상 임상시험 Topline data 수령)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (OliX) regarding the receipt of 'Topline data' from a Phase 2a clinical trial. It details the trial methodology, results, and statistical significance. In the context of financial filings, announcements regarding clinical trial results are classified as 'Regulatory Filings' (RNS) as they represent material corporate disclosures that do not fit into specific categories like Earnings Releases or M&A activity.
2023-04-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership and appointment of a specific individual (Kim Yang-gyun) as an executive (outside director) of Olix Co., Ltd. This is a standard regulatory filing for insider shareholding and director status changes, which falls under the 'Director's Dealing' category.
2023-03-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership and changes in holdings for a specific individual (Park Jun-hyun) who is an executive at Olix Co., Ltd. This type of filing is a standard regulatory requirement for insider trading or changes in executive shareholdings, which corresponds to the 'Director's Dealing' category.
2023-03-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.